drugset
drugset / Trial / NCT05106205

Phamacokinetics and Safety Profiles of DA-5213 10mg in Healthy Subjects

NCT05106205 ↗

Phase 1 Completed 40 enrolled Dong-A ST Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

Phamacokinetics and safety profiles of DA-5213 10mg in Healthy subjects

Timeline

Start
2021-12-21
Primary completion
2022-01-20
Completion
2022-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject DA-5213 Unknown 10 mg —
Subject DA-5213-R Unknown 10 mg —

Indications

No indication recorded.